Glaukos Corporation
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Glaukos Corporation's yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-2.6×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Higher than 59% of Healthcare companies in United States.
Cash Locked Ratio
$28For every $100 of sales, $28 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $21 tied up three years earlier.
More money tied up than 62% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 0/3Sales grew in 3 of the last 3 years; profit grew in 0 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
−$39Sales grew 79% in 3 years, but profit fell: $39 less profit per $100 of extra sales.
Lower than 81% of Healthcare companies in United States.
Asset Productivity Ratio
+79% / -11%In 3 years sales changed by +79% while total assets changed by -11%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
+2%Cash, after subtracting all debt, equals 2% of its market value (net cash).
Lower than 65% of Healthcare companies in United States.
Tangible Assets Ratio
77%Of every $100 the company owns, $77 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 55% of Healthcare companies in United States.
Tangible Net Worth Ratio
68%Of every $100 of net worth, $68 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 55% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Glaukos Corporation made a loss over the last year. Glaukos Corporation owes $0.26 for every $1 it owns. Glaukos Corporation made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossGlaukos Corporation made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
15.27The share price is 15.27 times Glaukos Corporation's book value per share, higher than 91% of Healthcare companies in United States.
Market cap
$10.4 BThe total market value of all of Glaukos Corporation's shares at today's price (share price × number of shares), larger than 90% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$682 MWhat Glaukos Corporation would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$11.57Net worth divided by the number of shares. The share price of $176.69 is 15.3 times this, which is the P/B above.
Return on equity (ROE)
-26.0%Glaukos Corporation lost 26.0% of its shareholders' money over the last year, higher than 63% of Healthcare companies in United States.
Owes vs Owns
0.26×Glaukos Corporation owes $0.26 for every $1 it owns (low), lower than 65% of Healthcare companies in United States.
Dividend yield
NoneGlaukos Corporation does not currently pay a dividend.
Revenue growth
+32%Revenue rose 32% in the year to Dec 2025, and grew 22% a year on average over 3 years.
Profit growth
LossGlaukos Corporation made a loss in each of the last two years.
Profit margin
-37.0%Glaukos Corporation lost $37 for every $100 of revenue.
Interest cover
Not coveredGlaukos Corporation's operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashGlaukos Corporation held $175 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Glaukos Corporation: $10.4 B ÷ $682 M (30 Jun 2026) = 15.3.
What is Glaukos Corporation's return on equity?
Glaukos Corporation lost 26.0% of its shareholders' money over the last year, higher than 63% of Healthcare companies in United States.
How much does Glaukos Corporation owe compared with what it owns?
Glaukos Corporation owes $0.26 for every $1 it owns (low), lower than 65% of Healthcare companies in United States.
Does Glaukos Corporation pay a dividend?
No. Glaukos Corporation does not currently pay a dividend.
Is Glaukos Corporation's revenue growing?
Revenue rose 32% in the year to Dec 2025, and grew 22% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.